Original Papers- TAKANO Tadao -
number of results to view: what to display: sort:
total:70
[2020]
1.Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology..[International journal of clinical oncology,25(3),(2020),403-417]Yoichi Naito, Saori Mishima, Kiwamu Akagi, Ataru Igarashi, Masafumi Ikeda, Susumu Okano, Shunsuke Kato, Tadao Takano, Katsuya Tsuchihara, Keita Terashima, Hiroshi Nishihara, Hiroyki Nishiyama, Eiso Hiyama, Akira Hirasawa, Hajime Hosoi, Osamu Maeda, Yasushi Yatabe, Wataru Okamoto, Shigeru Ono, Hiroaki Kajiyama, Fumio Nagashima, Yutaka Hatanaka, Mitsuru Miyachi, Yasuhiro Kodera, Takayuki Yoshino, Hiroya Taniguchi
10.1007/s10147-019-01610-y
http://www.ncbi.nlm.nih.gov/pubmed/31974683
[2019]
2.A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)..[International journal of clinical oncology,24(10),(2019),1284-1291]Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K, Suzuki M
10.1007/s10147-019-01471-5
http://www.ncbi.nlm.nih.gov/pubmed/31127479
3.An overview of ethical review committees in Japan: examining the certification applications of ethical review committees..[Nagoya journal of medical science,81(3),(2019),501-509]Iijima Y, Ogasawara K, Toda S, Takano T
10.18999/nagjms.81.3.501
http://www.ncbi.nlm.nih.gov/pubmed/31579340
4.Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition..[International journal of clinical oncology,(2019)]Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T
10.1007/s10147-019-01498-8
http://www.ncbi.nlm.nih.gov/pubmed/31286289
5.Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years..[Surgical oncology,29,(2019),25-32]Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD
10.1016/j.suronc.2019.02.002
http://www.ncbi.nlm.nih.gov/pubmed/31196490
6.A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m<sup>2</sup> cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors..[International journal of clinical oncology,24(5),(2019),575-582]Isohashi F, Takano T, Onuki M, Arimoto T, Kawamura N, Hara R, Kawano Y, Ota Y, Inokuchi H, Shinjo H, Saito T, Fujiwara S, Sawasaki T, Ando K, Horie K, Okamoto H, Murakami N, Hasumi Y, Kasamatsu T, Toita T
10.1007/s10147-018-01380-z
http://www.ncbi.nlm.nih.gov/pubmed/30580379
[2018]
7.Clinical utility of CA-125 in the management of uterine carcinosarcoma..[Journal of gynecologic oncology,29(6),(2018),e88-]Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD
10.3802/jgo.2018.29.e88
http://www.ncbi.nlm.nih.gov/pubmed/30207096
8.Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma..[Annals of surgical oncology,25(12),(2018),3676-3684]Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD
10.1245/s10434-018-6695-z
http://www.ncbi.nlm.nih.gov/pubmed/30105438
9.Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element..[Surgical oncology,27(3),(2018),433-440]Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD
10.1016/j.suronc.2018.05.017
http://www.ncbi.nlm.nih.gov/pubmed/30217299
10.Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma..[Annals of surgical oncology,25(9),(2018),2756-2766]Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD
10.1245/s10434-018-6547-x
http://www.ncbi.nlm.nih.gov/pubmed/29971677
11.Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery..[Journal of surgical oncology,117(3),(2018),488-496]Matsuo K, Johnson MS, Im DD, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Klobocista MM, Hasegawa K, Ueda Y, Shida M, Baba T, Satoh S, Yokoyama T, Machida H, Ikeda Y, Adachi S, Miyake TM, Iwasaki K, Yanai S, Takeuchi S, Nishimura M, Nagano T, Takekuma M, Shahzad MMK, Pejovic T, Omatsu K, Kelley JL, Ueland FR, Roman LD
10.1002/jso.24861
http://www.ncbi.nlm.nih.gov/pubmed/29044542
12.Significance of venous thromboembolism in women with uterine carcinosarcoma..[Gynecologic oncology,148(2),(2018),267-274]Matsuo K, Ross MS, Im DD, Klobocista MM, Bush SH, Johnson MS, Takano T, Blake EA, Ikeda Y, Nishimura M, Ueda Y, Shida M, Hasegawa K, Baba T, Adachi S, Yokoyama T, Satoh S, Machida H, Yanai S, Iwasaki K, Miyake TM, Takeuchi S, Takekuma M, Nagano T, Yunokawa M, Pejovic T, Omatsu K, Shahzad MMK, Kelley JL, Ueland FR, Roman LD
10.1016/j.ygyno.2017.11.036
http://www.ncbi.nlm.nih.gov/pubmed/29248197
13.Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study..[International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,28(1),(2018),2-10]Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A
10.1097/IGC.0000000000000602
http://www.ncbi.nlm.nih.gov/pubmed/26588236
[2017]
14.Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.[GYNECOLOGIC ONCOLOGY,147(3),(2017),565-571]Koji Matsuo, Malcolm S. Ross, Mayu Yunokawa, Marian S. Johnson, Hiroko Machida, Kohei Omatsu, Merieme M. Klobocista, Dwight D. Im, Shinya Satoh, Tsukasa Baba, Yuji Ikeda, Stephen H. Bush, Kosei Hasegawa, Erin A. Blake, Munetaka Takekuma, Masako Shida, Masako Nishimura, Sosuke Adachi, Tanja Pejovic, Satoshi Takeuchi, Takuhei Yokoyama, Yutaka Ueda, Keita Iwasaki, Takahito M. Miyake, Shiori Yanai, Tadayoshi Nagano, Tadao Takano, Mian M. K. Shahzad, Frederick R. Ueland, Joseph L. Kelley, Lynda D. Roman
10.1016/j.ygyno.2017.10.008
http://www.ncbi.nlm.nih.gov/pubmed/29056442 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000418208700014&DestApp=WOS
15.Phase I study of nivolumab combined with IFN-beta for patients with advanced melanoma.[ONCOTARGET,8(41),(2017),71181-71187]Taku Fujimura, Takanori Hidaka, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Hisayuki Tono, Akira Tsukada, Takahiro Haga, Akira Hashimoto, Ryo Morimoto, Takuhiro Yamaguchi, Tadao Takano, Setsuya Aiba
10.18632/oncotarget.17090
http://www.ncbi.nlm.nih.gov/pubmed/29050354 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000411153300160&DestApp=WOS
16.A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).[CANCER CHEMOTHERAPY AND PHARMACOLOGY,80(2),(2017),355-361]Tadahiro Shoji, Eriko Takatori, Hideo Omi, Masahiro Kagabu, Tatsuya Honda, Masayuki Futagami, Yoshihito Yokoyama, Michiko Kaiho, Hideki Tokunaga, Takeo Otsuki, Tadao Takano, Nobuo Yaegashi, Takanobu Kojimahara, Tsuyoshi Ohta, Satoru Nagase, Shu Soeda, Takafumi Watanebe, Hiroshi Nishiyama, Toru Sugiyama
10.1007/s00280-017-3363-0
http://www.ncbi.nlm.nih.gov/pubmed/28656383 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000406638200013&DestApp=WOS
17.Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.[GYNECOLOGIC ONCOLOGY,145(1),(2017),78-87]Koji Matsuo, Kohei Omatsu, Malcolm S. Ross, Marian S. Johnson, Mayu Yunokawa, Merieme M. Klobocista, Dwight D. Im, Stephen H. Bush, Yutaka Ueda, Tadao Takano, Erin A. Blake, Kosei Hasegawa, Tsukasa Baba, Masako Shida, Shinya Satoh, Takuhei Yokoyama, Hiroko Machida, Sosuke Adachi, Yuji Ikeda, Keita Iwasaki, Takahito M. Miyake, Shiori Yanai, Masato Nishimura, Tadayoshi Nagano, Munetaka Takekuma, Satoshi Takeuchi, Tanja Pejovic, Mian Mk Shahzad, Frederick R. Ueland, Joseph L. Kelley, Lynda D. Roman
10.1016/j.ygyno.2017.02.001
http://www.ncbi.nlm.nih.gov/pubmed/28215838 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000398334300014&DestApp=WOS
18.Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.[GYNECOLOGIC ONCOLOGY,144(2),(2017),329-335]Koji Matsuo, Malcolm S. Ross, Stephen H. Bush, Mayu Yunokawa, Erin A. Blake, Tadao Takano, Yutaka Ueda, Tsukasa Baba, Shinya Satoh, Masako Shida, Yuji Ikeda, Sosuke Adachi, Takuhei Yokoyama, Munetaka Takekuma, Satoshi Takeuchi, Masato Nishimura, Keita Iwasaki, Shiori Yanai, Merieme M. Klobocista, Marian S. Johnson, Hiroko Machida, Kosei Hasegawa, Takahito M. Miyake, Tadayoshi Nagano, Tanja Pejovic, Mian M. K. Shahzad, Dwight D. Im, Kohei Omatsu, Frederick R. Ueland, Joseph L. Kelley, Lynda D. Roman
10.1016/j.ygyno.2016.11.042
http://www.ncbi.nlm.nih.gov/pubmed/27931750 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000392885200021&DestApp=WOS
[2016]
19.Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.[INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY,21(4),(2016),735-740]Masahiro Kagabu, Tadahiro Shoji, Kazuyuki Murakami, Hideo Omi, Tatsuya Honda, Fumiharu Miura, Yoshihito Yokoyama, Hideki Tokunaga, Tadao Takano, Tsuyoshi Ohta, Dai Shimizu, Naoki Sato, Shu Soeda, Takafumi Watanabe, Hidekazu Yamada, Hideki Mizunuma, Nobuo Yaegashi, Satoru Nagase, Toru Tase, Toru Sugiyama
10.1007/s10147-016-0946-4
http://www.ncbi.nlm.nih.gov/pubmed/26782958 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000380676900017&DestApp=WOS
20.Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.[INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,26(3),(2016),561-567]Seiya Sato, Muneaki Shimada, Tsuyoshi Ohta, Takanobu Kojimahara, Hideki Tokunaga, Tadao Takano, Satoshi Yamaguchi, Hiroshi Tanabe, Shin Nishio, Junzo Kigawa
10.1097/IGC.0000000000000650
http://www.ncbi.nlm.nih.gov/pubmed/26825829 http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=TohokuUniv&SrcApp=TohokuUniv&DestLinkType=FullRecord&KeyUT=WOS:000371570700021&DestApp=WOS
Page: [1] [2] [3] [4] [next]
BackTop
copyright(c)2005 Tohoku University